These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35512724)

  • 1. Venetoclax and acute myeloid leukaemia: an expanding new frontier.
    Sahasrabudhe KD; Mims AS
    Lancet Haematol; 2022 Jun; 9(6):e387-e389. PubMed ID: 35512724
    [No Abstract]   [Full Text] [Related]  

  • 2. Is venetoclax the new backbone of acute myeloid leukaemia therapy?
    Jain P; Mims AS
    Lancet Haematol; 2021 Aug; 8(8):e536-e537. PubMed ID: 34329570
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
    Karagiannis P; Alsdorf W; Tallarek AC; Blohm ME; Oelrich J; Waizenegger JS; Wolschke C; Hecher K; Singer D; Bokemeyer C; Fiedler W
    Br J Haematol; 2021 Jan; 192(2):e60-e63. PubMed ID: 33222152
    [No Abstract]   [Full Text] [Related]  

  • 4. Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.
    Jamy O; Lin K; Worth S; Bachiashvili K; Rangaraju S; Vachhani P; Bhatia R
    Br J Haematol; 2022 Aug; 198(3):e35-e37. PubMed ID: 35509246
    [No Abstract]   [Full Text] [Related]  

  • 5. Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
    Salhotra A; Tsai NC; Zhang J; Ngo D; Aribi A; Sandhu K; Ball B; Al-Malki M; Ali H; Koller P; Artz A; Forman S; Nakamura R; Stein A; Marcucci G; Aldoss I; Pullarkat V
    Br J Haematol; 2022 Mar; 196(6):e71-e74. PubMed ID: 34931310
    [No Abstract]   [Full Text] [Related]  

  • 6. Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.
    Liu Y; Zhu L; Lv Z; Mao L; Hu C; Wang J; Zhou Y; Jin J; Meng H; You L
    Br J Haematol; 2023 Jun; 201(5):995-999. PubMed ID: 36999439
    [No Abstract]   [Full Text] [Related]  

  • 7. Venetoclax in acute myeloid leukemia.
    Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Neri A; Morabito F; Vigna E; Gentile M
    Expert Opin Investig Drugs; 2023 Apr; 32(4):271-276. PubMed ID: 36933006
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study.
    Miyashita N; Onozawa M; Matsukawa T; Mori A; Hidaka D; Minauchi K; Shigematsu A; Hashiguchi J; Igarashi T; Kakinoki Y; Tsutsumi Y; Ibata M; Wakasa K; Fujimoto K; Ishihara T; Sakai H; Iyama S; Oyake T; Kondo T; Teshima T
    Br J Haematol; 2024 Apr; 204(4):1549-1553. PubMed ID: 38238885
    [No Abstract]   [Full Text] [Related]  

  • 9. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
    Ferrara F
    Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
    [No Abstract]   [Full Text] [Related]  

  • 10. Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
    Gangat N; Tefferi A
    Am J Hematol; 2024 Apr; 99(4):515-518. PubMed ID: 38375926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
    Tian FQ; Zhang LS; Li JH; Tang MQ; Jiang J; Cheng XH; Zhang XC; Jiang M
    Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):694-696. PubMed ID: 32942828
    [No Abstract]   [Full Text] [Related]  

  • 12. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
    Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
    Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.
    Shoumariyeh K; Jung J; Rassner M; Dold SM; Riebl V; Pantic M; Herget G; Marks R; Lübbert M; Wäsch R; Engelhardt M
    Ann Hematol; 2021 Jun; 100(6):1637-1640. PubMed ID: 33712868
    [No Abstract]   [Full Text] [Related]  

  • 14. [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
    Zong LH; Wu XX; Zhang J; Li MY; Song BQ; Kong JY; Kong X; Hu XH; Bao XB; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):861-864. PubMed ID: 34788928
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity of venetoclax against relapsed acute undifferentiated leukemia.
    Caldwell KJ; Budhraja A; Opferman JT; Pui CH; Klco JM; Rubnitz JE
    Cancer; 2021 Aug; 127(15):2608-2611. PubMed ID: 33823069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia.
    Kennedy VE; Hui G; Azenkot T; Gaut D; Wieduwilt MJ; Oliai C; Jonas BA; Mittal V; Logan AC; Muffly LS; Mannis GN
    Am J Hematol; 2022 Jun; 97(6):E191-E194. PubMed ID: 35266185
    [No Abstract]   [Full Text] [Related]  

  • 17. Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment.
    Naka R; Kondo T; Nishikubo M; Muranushi H; Ueda Y; Oka T; Wada F; Kanda J; Yamamoto S; Watanabe M; Okada S; Imada K; Nakabo Y; Mizutani Y; Nannya Y; Ogawa S; Ishikawa T
    Am J Hematol; 2023 Sep; 98(9):E251-E254. PubMed ID: 37381699
    [No Abstract]   [Full Text] [Related]  

  • 18. [Retrospective analysis of the efficacy and safety of Venetoclax-based regimen in the treatment of 12 cases of acute myeloid leukemia with t (8; 21)].
    Mi RH; Chen L; Wang L; Ai H; Yin QS; Wei XD
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):501-504. PubMed ID: 37550208
    [No Abstract]   [Full Text] [Related]  

  • 19. The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
    Patel SA
    Br J Haematol; 2024 Apr; 204(4):1137-1138. PubMed ID: 38339780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.
    Lim B; Yoo D; Chun Y; Go A; Cho KJ; Choi D; Jung ME; Lee HY; Boohaker RJ; Lee JS; Jung D; Choi G
    Blood Cancer J; 2022 Apr; 12(4):57. PubMed ID: 35410412
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.